Word

SALUBRIS

Status

Dead

Status Code

404

Status Date

Tuesday, May 12, 2020

Serial Number

79083827

Registration Number

3972681

Registration Date

Tuesday, June 7, 2011

Mark Type

5000

Filing Date

Tuesday, May 11, 2010

Published for Opposition

Tuesday, March 22, 2011

Cancellation Date

Tuesday, May 12, 2020

Trademark Owner History

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD - Original Registrant
SHENZHEN SALUBRIS PHARMACEUTICALS; CO.,LTD - Owner At Publication

Classifications

5 Pharmaceutical preparations, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; chemico-pharmaceutical preparations, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; chemical preparations for pharmaceutical purposes, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; medicines for human purposes, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; troches, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; pharmaceutical products, namely, active pharmaceutical ingredients which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; prepared Chinese medicines, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; biochemical medicines, namely, for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; dietetic substances adapted for medical use, namely, beverages or food which are used for treating diseases of cardiovascular system, for use in hematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; capsules for pharmaceutical purposes containing pharmaceutical preparations, specifically for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; drugs for medical purposes, namely, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases

Color is not claimed as a feature of the mark.

Trademark Events

Dec 4, 2020

Notification Of Effect Of Cancellation Of Intl Reg E-Mailed

Dec 4, 2020

Death Of International Registration

Sep 27, 2019

Total Invalidation Processed By The Ib

Jul 1, 2019

Generic Madrid Transaction Sent To Ib

Jul 1, 2019

Generic Madrid Transaction Created

Jun 12, 2019

Total Invalidation Of Reg Ext Protection Created

Oct 12, 2018

Cancelled Section 71

Oct 10, 2018

Case Assigned To Post Registration Paralegal

Jan 3, 2018

Post Registration Action Mailed - Sec.71

Dec 19, 2017

Case Assigned To Post Registration Paralegal

Dec 6, 2017

Teas Section 71 Received

Dec 6, 2017

Teas Change Of Correspondence Received

Feb 25, 2013

Final Decision Transaction Processed By Ib

Nov 1, 2011

Final Disposition Notice Sent To Ib

Nov 1, 2011

Final Disposition Processed

Sep 7, 2011

Final Disposition Notice Created, To Be Sent To Ib

Jun 7, 2011

Registered-Principal Register

Mar 22, 2011

Published For Opposition

Mar 3, 2011

Notification Of Possible Opposition Sent To Ib

Mar 3, 2011

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Mar 2, 2011

Notice Of Publication

Feb 16, 2011

Law Office Publication Review Completed

Feb 11, 2011

Assigned To Lie

Jan 20, 2011

Correspondence Mailed

Jan 19, 2011

Approved For Pub - Principal Register

Jan 19, 2011

Examiner's Amendment Entered

Jan 19, 2011

Examiners Amendment -Written

Jan 19, 2011

Teas/Email Correspondence Entered

Jan 19, 2011

Correspondence Received In Law Office

Jan 19, 2011

Teas Response To Office Action Received

Sep 18, 2010

Refusal Processed By Ib

Aug 25, 2010

Non-Final Action Mailed - Refusal Sent To Ib

Aug 25, 2010

Refusal Processed By Mpu

Aug 25, 2010

Non-Final Action (Ib Refusal) Prepared For Review

Aug 24, 2010

Non-Final Action Written

Aug 24, 2010

Assigned To Examiner

Jul 23, 2010

Application Filing Receipt Mailed

Jul 19, 2010

New Application Office Supplied Data Entered In Tram

Jul 15, 2010

Sn Assigned For Sect 66a Appl From Ib